Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
9.670
Open
9.480
VWAP
9.57
Vol
79.69K
Mkt Cap
210.35M
Low
9.480
Amount
762.51K
EV/EBITDA(TTM)
--
Total Shares
17.37M
EV
203.30M
EV/OCF(TTM)
--
P/S(TTM)
3.10
Exagen Inc. is a provider of autoimmune diagnostics focused on transforming care for patients with chronic and debilitating autoimmune conditions. The Company is focused on the design, development and commercialization of a portfolio of testing products under its AVISE brand, which allow for the differential diagnosis, prognosis and monitoring of complex rheumatic, autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its testing products are supported by two proprietary technologies: its AVISE Lupus platform, which incorporates Cell-Bound Complement Activation Products (CB-CAPs) for diagnosing SLE, and a set of three biomarkers, the t-cell-based CB-CAP TC4d, along with two t-cell antibodies, TIgG, and TIgM (the T-Cell Biomarkers), all of which are incorporated into its AVISE CTD product. The Company’s flagship product, AVISE CTD, enables clinicians to more effectively diagnose complex autoimmune conditions.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
FY2026Q1
16.89M
+35.02%
-0.158
-43.75%
17.68M
+29.48%
-0.135
-32.5%
17.96M
+15.86%
-0.100
-50%
Estimates Revision
The market is revising Upward the revenue expectations for Exagen Inc. (XGN) for FY2025, with the revenue forecasts being adjusted by 2.16% over the past three months. During the same period, the stock price has changed by 70.43%.
Revenue Estimates for FY2025
Revise Upward
+2.16%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+23.09%
In Past 3 Month
Stock Price
Go Up
+70.43%
In Past 3 Month
7 Analyst Rating
16.41% Upside
Wall Street analysts forecast XGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for XGN is 11.17 USD with a low forecast of 10.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Buy
0 Hold
0 Sell
Strong Buy
16.41% Upside
Current: 9.595
Low
10.00
Averages
11.17
High
12.00
16.41% Upside
Current: 9.595
Low
10.00
Averages
11.17
High
12.00
KeyBanc
Sector Weight -> Overweight
upgrade
$12
2025-07-30
Reason
KeyBanc
Price Target
$12
2025-07-30
upgrade
Sector Weight -> Overweight
Reason
KeyBanc last night upgraded Exagen to Overweight from Sector Weight with a $12 price target. The firm sees higher revenue visibility due to the company's improved pricing, salesforce additions, and new payers like Tricare. Exagen is a leader in autoimmune diagnostics and its revenue guidance implies growth of 17%-25% in 2025, the analyst tells investors in a research note. KeyBanc believes the company is working to expand its leading market position in novel connective tissue diagnosis with new biomarkers in early 2026 to increase the "moat" around its core test.
Canaccord
Buy
maintain
$8 -> $11
2025-07-30
Reason
Canaccord
Price Target
$8 -> $11
2025-07-30
maintain
Buy
Reason
Canaccord raised the firm's price target on Exagen to $11 from $8 and keeps a Buy rating on the shares. The firm said the target increase is driven by increased near- and long-term revenue estimates, while noting the company announced 2Q25 results that were ahead of our estimates and FactSet consensus.
Cantor Fitzgerald
Overweight
maintain
$7 -> $10
2025-07-30
Reason
Cantor Fitzgerald
Price Target
$7 -> $10
2025-07-30
maintain
Overweight
Reason
Cantor Fitzgerald raised the firm's price target on Exagen to $10 from $7 and keeps an Overweight rating on the shares. The company reported strong Q2 operating results and raised the top-end of FY25 revenue guidance, the analyst tells investors in a research note. Cantor remains excited about Exagen as the company continues to roll out new biomarkers that stand to improve sensitivity, which should result in incremental adoption in addition to being accretive to average selling price.
KeyBanc
Sector Weight -> Overweight
upgrade
$12
2025-07-29
Reason
KeyBanc
Price Target
$12
2025-07-29
upgrade
Sector Weight -> Overweight
Reason
KeyBanc upgraded Exagen to Overweight from Sector Weight with a $12 price target.
Craig-Hallum
NULL -> Buy
initiated
$12
2025-07-23
Reason
Craig-Hallum
Price Target
$12
2025-07-23
initiated
NULL -> Buy
Reason
Craig-Hallum initiated coverage of Exagen with a Buy rating and $12 price target.
Craig-Hallum
initiated
$12
2025-07-23
Reason
Craig-Hallum
Price Target
$12
2025-07-23
initiated
Reason
As previously reported, Craig-Hallum initiated coverage of Exagen with a Buy rating and $12 price target. Exagen performs a proprietary diagnostic panel to more effectively diagnose autoimmune diseases like lupus and rheumatoid arthritis. These conditions are notoriously difficult to diagnose, and the Exagen panel has been shown to simplify the diagnostic odyssey and increase the number of patients diagnosed, the firm notes. Craig-Hallum is looking for inflection to volume growth, accelerating revenue growth, margin expansion, and EBITDA breakeven on the horizon, with estimates that feel conservative and the shares trading at less than 2-turns EV/2026 sales.
See All Ratings
Valuation Metrics
The current forward P/E ratio for Exagen Inc (XGN.O) is -19.71, compared to its 5-year average forward P/E of -4.68. For a more detailed relative valuation and DCF analysis to assess Exagen Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.68
Current PE
-19.71
Overvalued PE
-0.83
Undervalued PE
-8.54
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
-7.30
Current EV/EBITDA
-86.36
Overvalued EV/EBITDA
7.72
Undervalued EV/EBITDA
-22.31
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
Fair
5Y Average PS
2.13
Current PS
2.87
Overvalued PS
3.71
Undervalued PS
0.55
Financials
Annual
Quarterly
FY2025Q2
YoY :
+14.19%
17.20M
Total Revenue
FY2025Q2
YoY :
+1.66%
-2.63M
Operating Profit
FY2025Q2
YoY :
+49.66%
-4.44M
Net Income after Tax
FY2025Q2
YoY :
+31.25%
-0.21
EPS - Diluted
FY2025Q2
YoY :
+20.77%
-3.09M
Free Cash Flow
FY2025Q2
YoY :
+0.52%
60.43
Gross Profit Margin - %
FY2025Q2
YoY :
+31.08%
-25.81
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
1.2M
USD
1
6-9
Months
0.0
USD
0
0-12
Months
660.0K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
134.8K
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
0
0.0
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
1.2M
USD
1
6-9
Months
0.0
USD
0
0-12
Months
660.0K
USD
1
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
2
134.8K
USD
Months
XGN News & Events
Events Timeline
2025-07-29 (ET)
2025-07-29
08:02:35
Exagen sees FY25 revenue $65M-$70M, consensus $65.87M
2025-07-29
08:02:11
Exagen reports Q2 EPS (21c), consensus (15c)
2025-06-23 (ET)
2025-06-23
09:08:36
Exagen appoints Michael Mahler as CSO
Sign Up For More Events
Sign Up For More Events
News
4.0
07-30BenzingaCanaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11
9.5
07-29NASDAQ.COMExagen Inc Q2 Loss Increases, Misses Estimates
4.0
07-23BenzingaCraig-Hallum Initiates Coverage On Exagen with Buy Rating, Announces Price Target of $12
Sign Up For More News
People Also Watch
FAQ
What is Exagen Inc (XGN) stock price today?
The current price of XGN is 9.595 USD — it has increased 0.37 % in the last trading day.
What is Exagen Inc (XGN)'s business?
What is the price predicton of XGN Stock?
What is Exagen Inc (XGN)'s revenue for the last quarter?
What is Exagen Inc (XGN)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Exagen Inc (XGN)'s fundamentals?
How many employees does Exagen Inc (XGN). have?